As has been reported in other cancer types21–23, we found that CCR8 was selectively expressed on tumor-infiltrating Tregs in human lung cancer, and CCR8 expression on other immune cells was very low, indicating that adverse events may not be a concern for CCR8-targeted therapy. The gene discussed is CCR8; the disease is lung carcinoma.